Bank of New York Mellon Corp Buys 3,321 Shares of Omeros Corporation (NASDAQ:OMER)

Bank of New York Mellon Corp raised its stake in shares of Omeros Corporation (NASDAQ:OMER) by 2.2% in the first quarter, Holdings Channel.com reports. The institutional investor owned 151,062 shares of the biopharmaceutical company’s stock after buying an additional 3,321 shares during the quarter. Bank of New York Mellon Corp’s holdings in Omeros were worth $1,242,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Nomura Holdings Inc. boosted its holdings in shares of Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after buying an additional 430,932 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Omeros in the fourth quarter worth approximately $1,488,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Omeros during the 4th quarter worth $1,033,000. Ancora Advisors LLC grew its position in shares of Omeros by 1,036.4% during the 4th quarter. Ancora Advisors LLC now owns 85,800 shares of the biopharmaceutical company’s stock valued at $848,000 after acquiring an additional 78,250 shares during the period. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Omeros during the 1st quarter valued at $579,000. 48.79% of the stock is owned by institutional investors.

Omeros Stock Performance

Shares of Omeros stock opened at $3.85 on Thursday. Omeros Corporation has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The company has a market capitalization of $237.78 million, a P/E ratio of -1.45 and a beta of 2.16. The company has a fifty day moving average of $3.41 and a 200 day moving average of $6.20.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Analysts forecast that Omeros Corporation will post -3.09 EPS for the current year.

Analyst Upgrades and Downgrades

OMER has been the topic of a number of recent research reports. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a report on Friday, June 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, May 16th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Friday, July 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Omeros in a report on Friday, June 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.